Since 1996, he has run a commercial consultancy working with a wide range of customers in the fields of pharmaceuticals, diagnostics and medical devices. The company specialises in the evaluation and analysis of trials and clinical meta-data to inform the design and development of epidemiological and economic models in support of market access, which are then used to optimize the chances of regulatory approval and health-care commissioner uptake. Commercial customers have ranged from the smallest med-tech companies up to the largest trans-national pharmaceutical manufacturers.
Working alongside NHS England as part of the SBRI funding process, he has assisted in early stage evaluation and consultancy with around 150 UK medical device start-ups over the past 7 years, in addition to carrying out in-depth consultancy with companies as they progress to market-readiness.
He has published extensively in the market access field, with in excess of 50 peer-reviewed publications to date. In addition, he has contributed to a wide range of regulatory and Health Technology Assessment submissions in both the UK and Europe.